Multiparametric MRI Study of Endogenous Analgesia and Prediction the Efficacy of Migraine Pharmacological Prevention
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To delineate brain mechanisms that subserve EA in the healthy state and to identify alterations in mechanisms supporting EA in chronic pain and their therapeutic relevance. Individuals with migraine will be examined between episodes in order to assess basal alterations in the efficiency of spatial and temporal filtering of noxious information. This population provides the unique opportunity to examine such processes without confounds arising from ongoing pain.
| Condition | Intervention |
|---|---|
|
Migraine |
Drug: Doluxetine Drug: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
- Therapeutic response to the analgesic drugs [ Time Frame: 2 month ] [ Designated as safety issue: No ]The level of pain relief
| Estimated Enrollment: | 100 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: Placebo |
Drug: Doluxetine
30 mg/d
Other Name: duloxetine
Drug: Placebo
suger pill 30mg/d
Other Name: sugar
|
|
Active Comparator: treatment
Duloxetine will be given in a daily dose of 30 mg for 5 weeks
|
Drug: Doluxetine
30 mg/d
Other Name: duloxetine
Drug: Placebo
suger pill 30mg/d
Other Name: sugar
|
Detailed Description:
Pain is a uniquely individual experience that is powerfully shaped by the action of descending control mechanisms. These systems may play crucial roles in the moment-to-moment tuning of the sensitivity, spatial, and temporal response characteristics of nociceptive processing mechanisms during both acute and pathological pain states. However, these systems remain poorly understood in human subjects. The proposed research will use psychophysics and multiparametric MRI to (i) delineate the brain mechanisms that subserve and regulate endogenous analgesia (EA) in the healthy state and (ii) to identify alterations in mechanisms supporting EA in chronic pain and their therapeutic relevance. In both healthy subjects and chronic pain patients, EA will be probed using the DNIC (diffuse noxious inhibitory controls) and offset analgesia paradigms. Functional MRI will examine activation of brainstem mechanisms important in EA, while both functional and structural connectivity analyses will assess the regulation of these brainstem mechanisms by cerebral cortical regions involved in attention and affect. One pathological painful condition, migraine, will be examined since it allows changes in EA associated with chronic pain to be investigated between episodes of pain. Finally, EA and EA associated structural and functional parameters will be used to predict the efficacy of one compound, amitriptyline, to treat migraine in individual patients. Taken together, the proposed research will provide substantial insights into basic mechanisms supporting and regulating EA and can provide a foundation for mechanism-based individualized choice of therapy that may benefit all chronic pain patients.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- patients diagnosed with migraine based on the International Headache Society (IHS) criteria 1 that have >4 attacks/month, both with and without aura
Exclusion Criteria:
- patients receiving any migraine preventive treatment during last 3 months or prior treatment with amytriptiline
- other chronic pain conditions
- psychiatric, other neurological diseases, language barrier or cognitive dysfunction
Contacts and Locations| Contact: David Yarnitsky, MD, PhD | 0728542605 | d_yarnitsky@rambam.health.gov.il |
| Israel | |
| Rambam health care campus | Not yet recruiting |
| Haifa, Israel | |
| Contact: David Yarnitsky 9728542605 d_yarnitsky@rambam.health.gov.il | |
More Information
No publications provided
| Responsible Party: | d_yarnitsky, Head of Neurology Department, Rambam Health Care Campus |
| ClinicalTrials.gov Identifier: | NCT01470352 History of Changes |
| Other Study ID Numbers: | Migrain-0265-11CTIL |
| Study First Received: | November 9, 2011 |
| Last Updated: | November 10, 2011 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Rambam Health Care Campus:
|
migraine pain CPM offset analgesia fMRI |
Additional relevant MeSH terms:
|
Migraine Disorders Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Duloxetine Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Serotonin Agents Physiological Effects of Drugs Adrenergic Uptake Inhibitors Adrenergic Agents Dopamine Uptake Inhibitors Dopamine Agents Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 17, 2013